BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

...applications. “I would fully expect unique tau signatures for different tauopathies, like fingerprints.” Joel Braunstein, C2N Diagnostics...
...Washington University in St. Louis led by Randall Batemen, who is also scientific co-founder of C2N Diagnostics LLC...
...one of these markers is that they only tell part of the story.” Joel Braunstein, C2N Diagnostics...
BioCentury | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

...are the only two to reach Phase II for PSP. AbbVie holds ABBV-8E12’s rights from C2N Diagnostics LLC...
BioCentury | Jun 22, 2019
Product Development

Is tau the new amyloid?

...from Biogen Inc. and partner Bristol-Myers Squibb Co., and ABBV-8E12 from AbbVie Inc. and partner C2N Diagnostics LLC...
...Cambridge, Mass. Brigham and Women’s Hospital, Boston, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. C2N Diagnostics LLC...
BioCentury | Feb 23, 2018
Company News

Voyager, AbbVie to develop anti-tau gene therapies

...tau in neurofibrillary tangles in the brain. AbbVie obtained rights to ABBV-8E12 in 2015 from C2N Diagnostics LLC...
BioCentury | Feb 20, 2018
Company News

Voyager, AbbVie partner for AD gene therapies

...tau in neurofibrillary tangles in the brain. AbbVie obtained rights to ABBV-8E12 in 2015 from C2N Diagnostics LLC...
BioCentury | May 25, 2017
Company News

Merck obtains rights to Teijin's tau candidate

...tau in neurofibrillary tangles in the brain. AbbVie obtained its rights in 2015 from from C2N Diagnostics LLC...
...from Bristol-Myers Squibb (NYSE:BMY) (see BioCentury Extra, April 13) . Jaime De Leon ABBV-8E12 ACI-35 C2N-8E12 LMTX Tau Vaccine TRx0237 AbbVie Inc. AC Immune S.A. C2N Diagnostics LLC Merck...
BioCentury | Feb 1, 2017
Clinical News

ABBV-8E12: Ph II started

...rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015 ). C2N Diagnostics LLC...
...Severity (CGI-S), CGI of Change (CGI-C) and pharmacokinetics Status: Phase II started Milestone: NA Julian Zhu ABBV-8E12 C2N-8E12 AbbVie Inc. C2N Diagnostics LLC Microtubule-associated...
BioCentury | Jan 27, 2017
Clinical News

ABBV-8E12: Ph II started

...rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015 ). C2N Diagnostics LLC...
...Neuropsychological Status (RBANS), functional activities questionnaire and pharmacokinetics Status: Phase II started Milestone: NA Julian Zhu ABBV-8E12 C2N-8E12 AbbVie Inc. C2N Diagnostics LLC Microtubule-associated...
BioCentury | Dec 17, 2016
Product Development

Not dead yet

...J&J, as well as for the antibody are expected in 1H17. ABBV-8E12 from AbbVie and C2N Diagnostics LLC...
...S.A. (NASDAQ:ACIU), Lausanne, Switzerland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. C2N Diagnostics LLC...
BioCentury | Jul 28, 2016
Targets & Mechanisms

Effectorless efficacy

...mAbs in development include BMS-986168 from Bristol-Myers Squibb Co. and ABBV-8E12 from AbbVie Inc. and C2N Diagnostics LLC...
...S.A., Lausanne, Switzerland Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. C2N Diagnostics LLC...
Items per page:
1 - 10 of 17
BioCentury | Aug 1, 2020
Tools & Techniques

A plasma tau marker gains support for diagnosing Alzheimer’s disease

...applications. “I would fully expect unique tau signatures for different tauopathies, like fingerprints.” Joel Braunstein, C2N Diagnostics...
...Washington University in St. Louis led by Randall Batemen, who is also scientific co-founder of C2N Diagnostics LLC...
...one of these markers is that they only tell part of the story.” Joel Braunstein, C2N Diagnostics...
BioCentury | Dec 13, 2019
Clinical News

Phase II miss dims outlook for Biogen’s anti-tau mAb from Bristol deal

...are the only two to reach Phase II for PSP. AbbVie holds ABBV-8E12’s rights from C2N Diagnostics LLC...
BioCentury | Jun 22, 2019
Product Development

Is tau the new amyloid?

...from Biogen Inc. and partner Bristol-Myers Squibb Co., and ABBV-8E12 from AbbVie Inc. and partner C2N Diagnostics LLC...
...Cambridge, Mass. Brigham and Women’s Hospital, Boston, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. C2N Diagnostics LLC...
BioCentury | Feb 23, 2018
Company News

Voyager, AbbVie to develop anti-tau gene therapies

...tau in neurofibrillary tangles in the brain. AbbVie obtained rights to ABBV-8E12 in 2015 from C2N Diagnostics LLC...
BioCentury | Feb 20, 2018
Company News

Voyager, AbbVie partner for AD gene therapies

...tau in neurofibrillary tangles in the brain. AbbVie obtained rights to ABBV-8E12 in 2015 from C2N Diagnostics LLC...
BioCentury | May 25, 2017
Company News

Merck obtains rights to Teijin's tau candidate

...tau in neurofibrillary tangles in the brain. AbbVie obtained its rights in 2015 from from C2N Diagnostics LLC...
...from Bristol-Myers Squibb (NYSE:BMY) (see BioCentury Extra, April 13) . Jaime De Leon ABBV-8E12 ACI-35 C2N-8E12 LMTX Tau Vaccine TRx0237 AbbVie Inc. AC Immune S.A. C2N Diagnostics LLC Merck...
BioCentury | Feb 1, 2017
Clinical News

ABBV-8E12: Ph II started

...rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015 ). C2N Diagnostics LLC...
...Severity (CGI-S), CGI of Change (CGI-C) and pharmacokinetics Status: Phase II started Milestone: NA Julian Zhu ABBV-8E12 C2N-8E12 AbbVie Inc. C2N Diagnostics LLC Microtubule-associated...
BioCentury | Jan 27, 2017
Clinical News

ABBV-8E12: Ph II started

...rights to develop and commercialize the product from C2N (see BioCentury, April 13, 2015 ). C2N Diagnostics LLC...
...Neuropsychological Status (RBANS), functional activities questionnaire and pharmacokinetics Status: Phase II started Milestone: NA Julian Zhu ABBV-8E12 C2N-8E12 AbbVie Inc. C2N Diagnostics LLC Microtubule-associated...
BioCentury | Dec 17, 2016
Product Development

Not dead yet

...J&J, as well as for the antibody are expected in 1H17. ABBV-8E12 from AbbVie and C2N Diagnostics LLC...
...S.A. (NASDAQ:ACIU), Lausanne, Switzerland AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. C2N Diagnostics LLC...
BioCentury | Jul 28, 2016
Targets & Mechanisms

Effectorless efficacy

...mAbs in development include BMS-986168 from Bristol-Myers Squibb Co. and ABBV-8E12 from AbbVie Inc. and C2N Diagnostics LLC...
...S.A., Lausanne, Switzerland Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. C2N Diagnostics LLC...
Items per page:
1 - 10 of 17